About Quratis
Quratis is a company based in Seoul (South Korea) founded in 2016.. Quratis offers products and services including QTP101, QTP104, CPP Platform, Peptide Nucleic Acid Complexes, and CMO&CDMO Services. Quratis operates in a competitive market with competitors including Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
- Headquarter Seoul, South Korea
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name (주)큐라티스
- Jurisdiction Na, Maharashtra, India
-
Annual Revenue
$253.44 K (USD)-63.71as on Dec 31, 2024
-
Net Profit
$-17.81 M (USD)-54.6as on Dec 31, 2024
-
EBITDA
$-10.32 M (USD)-25.65as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Quratis
Quratis offers a comprehensive portfolio of products and services, including QTP101, QTP104, CPP Platform, Peptide Nucleic Acid Complexes, and CMO&CDMO Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Tuberculosis vaccine combining antigens and immune enhancers.
COVID-19 mRNA vaccine for viral protection.
Platform for cell-penetrating peptides in drug transport.
Complexes for nucleic acid binding and therapeutic applications.
Custom services for biological product development and production.
Funding Insights of Quratis
- Total Funding Total Funding
- Total Rounds 1
- Last Round Last Round
- First Round First Round
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2023 | Amount | Seed - Quratis | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Quratis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Quratis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Quratis Comparisons
Competitors of Quratis
Quratis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small molecule inhibitors for rare lung diseases
|
|
| domain | founded_year | HQ Location |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| domain | founded_year | HQ Location |
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
|
|
| domain | founded_year | HQ Location |
Late-stage biopharma antibiotics for gynecological infections are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines for viral infections are developed by the company.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Quratis
Frequently Asked Questions about Quratis
When was Quratis founded?
Quratis was founded in 2016 and raised its 1st funding round 7 years after it was founded.
Where is Quratis located?
Quratis is headquartered in Seoul, South Korea.
Who is the current CEO of Quratis?
Kwan-Goo Cho is the current CEO of Quratis.
What is the annual revenue of Quratis?
Annual revenue of Quratis is $253.44K as on Dec 31, 2024.
What does Quratis do?
Quratis was founded in 2016 in Seoul, South Korea, within the biotechnology sector. Focus is placed on developing vaccines and cell therapies to address tuberculosis. The lead program involves the ID93 fusion protein paired with the GLA-SE adjuvant, which has completed Phase I clinical trials. This approach aims to strengthen immune responses generated by the BCG vaccine, supporting ongoing efforts in infectious disease treatment.
Who are the top competitors of Quratis?
Quratis's top competitors include Insmed, Basilea and Eligo Bioscience.
What products or services does Quratis offer?
Quratis offers QTP101, QTP104, CPP Platform, Peptide Nucleic Acid Complexes, and CMO&CDMO Services.